Novo Nordisk continued to grow into the diabetes market, and is projected to be the No. 1 company in worldwide diabetes sales.
Despite difficult conditions, Novartis is increasing sales through the launch of innovative therapies, a clear focus on growth markets, and productivity-oriented cost control.
The leaders of Merck have picked their priorities – immuno-oncology, Alzheimer’s, HCV, and externally sourced R&D – and are reshaping their company accordingly.
With more than a third of its 2011 revenue now off-patent, Eli Lilly is looking to its late-stage pipeline to restore the company’s fortunes.
Johnson & Johnson is the global healthcare sales leader, successfully delivering strong results via all four of the company’s long-term growth platforms.
